Guest
It’s a game-changer for veterinary professionals treating canine parvovirus — Elanco’s USDA conditionally approved Canine Parvovirus Monoclonal Antibody (CPMA) treatment for fighting this deadly, highly transmissible disease. This treatment, which is the first monoclonal antibody, is given in a single intravenous dose. It’s the only targeted treatment available for parvo, which is a devastating disease that affects an estimated 300k dogs each year.1 It can be given to all dogs and puppies at least eight weeks old that test positive. Join Dr. Kristin Zersen, a veterinary critical care specialist, as she explains how canine parvovirus impacts her clinical day and how she’s incorporating Canine Parvovirus Monoclonal Antibody into her parvo treatment protocols.
